Posted in | News | Molybdenum | Tungsten

Woulfe Mining Announces Assay Results from Sangdong Tungsten Mine

Woulfe Mining has reported assay results from the six and seven set of samples connected with the phase 1 drilling completed recently at the Sangdong tungsten mine.

The molybdenum-tungsten mineralization at Sangdong is present in three analogous, shallow-dipping skarn zones, namely Main, Hangingwall and Footwall, with a lateral area of up to 1,500 m down dip and 1,200 m along strike.

The company has intersected 0.99% WO3 over 8.0 m in the hole SD 97 at the Main zone, 0.87% WO3 over 17.3 m and 0.56% WO3 over 12.0 m in the hole SD 97 at the Hangingwall zone and 0.68% WO3 over 8.2 m in the hole SD 95 and 0.36% WO3 over 15.6 m in the hole WSDD0027 at the Footwall zone.

The company’s drilling program has targeted the mineralization, which is unexplored, in the mine’s upper part above the existing water level for the purpose of mine planning and feasibility reserve evaluation. Woulfe has received 103.6 mt as Inferred Resource at 0.04% MoS2, 0.35% WO3 at a cut-off of 0.1% WO3 through the 2010 March Wardrop Engineering Scoping Study. This resource estimate combined the group of Footwall mineralized zones as a unit and the Hangingwall Zone as an additional unit. It will not include any residual mineralization from the Main zone.

The assay results of the batches six and seven has included seven holes, which contains five surface holes and four were drilled to outline the deposit’s western margin. The location of SD 92, the fifth surface hole, is in the central part of the deposit to describe the Hangingwall zone.

The company has prepared the samples on-site in Korea and sent for analysis to SGS Perth, Australia. inductively coupled plasma mass spectrometry (ICP) examines the samples and aqua regia or 4-acid digestion tests the for ore-grade quantities of definite elements. Molybdenum is examined by X-ray fluorescence.

Source: http://www.woulfemining.com/

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 18). Woulfe Mining Announces Assay Results from Sangdong Tungsten Mine. AZoMining. Retrieved on May 25, 2024 from https://www.azomining.com/News.aspx?newsID=4364.

  • MLA

    Scanlon, Joel. "Woulfe Mining Announces Assay Results from Sangdong Tungsten Mine". AZoMining. 25 May 2024. <https://www.azomining.com/News.aspx?newsID=4364>.

  • Chicago

    Scanlon, Joel. "Woulfe Mining Announces Assay Results from Sangdong Tungsten Mine". AZoMining. https://www.azomining.com/News.aspx?newsID=4364. (accessed May 25, 2024).

  • Harvard

    Scanlon, Joel. 2019. Woulfe Mining Announces Assay Results from Sangdong Tungsten Mine. AZoMining, viewed 25 May 2024, https://www.azomining.com/News.aspx?newsID=4364.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.